Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ATTO
ATTOVIA THERAPEUTICS, INC.
NASDAQ
$23.66
▼ DOWN 7.40% (-1.89)

KEY STATISTICS

Market Cap$1.05 B
52w High$28.00
52w Low$16.15
Dividend Yield—
Frequency—
P/E—
Volume267.43K
Shares Out.43.03M

COMPANY

LEADERSHIP

Tao Fu
CHIEF EXECUTIVE
Tao Fu

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 5, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
44

PRICE TARGET

Target High$52.00
Target Low$39.00
Target Median$45.00
Target Consensus$45.33

PRICE

$23.66 ▼ DOWN 7.40% (−$1.89)
$24.00$25.00$26.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM23.66

About Attovia Therapeutics, Inc.

https://www.attovia.com ↗

A clinical-stage biopharmaceutical company developing immune-mediated disease therapies using its ATTOBODY platform, with lead candidate ATTO-1310 targeting IL-31 for chronic pruritic conditions like atopic dermatitis.

INDUSTRY

Biotechnology

A PRODUCT ATTOVIA THERAPEUTICS, INC. IS KNOWN FOR

ATTO-1310
ATTO-1310

ATTO-1310, Attovia’s lead clinical-stage drug, targets interleukin-31 to treat severe itching and atopic dermatitis, aiming to become a best-in-class therapy for chronic pruritus.

COMPETITORS

COMPETITOR
ABBV COMPARE
LLY COMPARE
REGN COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTQ2-2026
Collaboration Revenue$450K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
WALSH COLIN
Purchase · 5.7K shares
2026-08-05
★
OTHER: FORMER 10% OWNER
GOLDMAN SACHS GROUP INC
Purchase · 28.7K shares
2026-08-05
★
DIRECTOR
WALSH COLIN
Purchase · 2.9K shares
2026-08-05
★
OTHER: FORMER 10% OWNER
GOLDMAN SACHS GROUP INC
Purchase · 2.9K shares
2026-08-05